Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2000
11/22/2000EP1052982A1 AMINOTETRALINS AS 5-HT 1D$g(a)? AGONISTS
11/22/2000EP0726267B1 Quinazoline derivatives
11/22/2000EP0705255B1 N-morpholino-n-nitrosaminoacetonitril cyclodextrin inclusion complexes
11/22/2000EP0701443B2 Terfenadine metabolites and their optically pure isomers for treating allergic disorders
11/22/2000EP0669936B1 Mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace
11/22/2000EP0586535B1 Methods and compositions based on inhibition of cell invasion and fibrosis by dextran sulfate
11/22/2000CN1274288A Peptide-containing & alpha; -ketoamide cysteine and serine protease inhibitors
11/22/2000CN1274285A Alpha-ketoamide multicatalytic protease inhibitors
11/22/2000CN1274284A Methods of modulating serine/threnoine protein kinase function with 5-azaquinoxaline-based compounds
11/22/2000CN1274283A Quinoline-containing & Alpha;-ketoamide cysteine and serine protease inhibitors
11/22/2000CN1274281A Compsns. for treating and preventing arterial thrombosis and use of factor Xa inhibitor on its own and/or combined with platelet antiaggegating agent
11/22/2000CN1273974A Camptothecin derviative, its prepn. method and medicinal compsns. containing same
11/22/2000CN1273967A Novel substituted dimeric compounds, its preparing process and medicinal compsns. containing same
11/22/2000CN1273850A Reagent for diagnosing eary urinary calculus
11/22/2000CN1058715C Thiophene compound, its prepn. method and medicinal compsn. containing same
11/22/2000CN1058710C Benzamide derivatives, process for prepn. thereof and pharmaceutical compsn. comprising same
11/22/2000CN1058629C 'Longteng' medicinal wine
11/21/2000US6150557 Compounds
11/21/2000US6150530 Amidation of amine with acid
11/21/2000US6150416 2-hydroxy-3-(substitued benzyl)-n,n'-bis(substituted carbonyl)-n-(substituted)-1,3-propanediamine based compounds; use in the detection, labelling and inhibition of cathepsin d
11/21/2000US6150415 Epoxide hydrolase complexes and methods therewith
11/21/2000US6150414 Inhibiting a virus causing infection (such as hiv) by administering the compound 1,3,4,6-tetrahydroxy-7,16-dioxo-7,16-dihydro-dibenzo(a,o)perylene
11/21/2000US6150407 In a tissue or organ by contacting with a compound of given formula such as methyl-3,5-diiodo-4-(4'-methoxyphenoxy)benzoate; reducing the level of tumor necrosis factor alpha
11/21/2000US6150397 5-aroylnaphthalene derivatives as anti-inflammatory agents
11/21/2000US6150388 Indole derivatives as 5-HT1 agonists
11/21/2000US6150384 Pharmaceutical composition
11/21/2000US6150383 Comprising an insulin sensitivity enhancer in combination with one or more other antidiabetics differing from the enhancer in mechanism of action; lipid/glycometabolism disorders; antidiabetic agents; side effect reduction
11/21/2000US6150378 Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
11/21/2000US6150377 Farnesyl protein transferase inhibitors; anticarcinogenic,-tumor and -proliferative agents; also psoriasis, benign prostatic hypertrophy or restinosis; infections facilitated by farnesyl protein transferase, e.g., malaria or hepatitus delta
11/21/2000US6150376 Bi- and tri-cyclic aza compounds and their uses
11/21/2000US6150375 Inhibitors of both of the human 5ar isozymes; benign prostate hyperplasia, male pattern baldness, acne vulgaris, seborrhea, androgenic alopecia, hirsutism and prostate cancer; blocks the conversion of testosterone to 5-alpha-dihydrotestosterone
11/21/2000US6150370 1,3-dinitrocyclic compound treats numerous diseases caused by undesired metalloprotease activity, such as tumor metastasis, osteoarthritis, rheumatoid arthritis, skin inflammation, ulcerations, and periodontitis
11/21/2000US6150359 Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
11/21/2000US6150358 Useful in the treatment of disease for which the use of anti-oxidation agent is requiered such as neurodegenrative disorders
11/21/2000US6150348 Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
11/21/2000US6150346 Method and composition for treating or preventing osteoporosis
11/21/2000US6150340 RNA-dependent amidotransferase from Staphylococcus aureus
11/21/2000US6150335 Treatment for pain
11/21/2000US6150330 Parenteral administration to the animal of a substantially aqueous biologically active bovine growth hormone releasing factor analog comprising at least 50 mg of said biologically active bovine hormone releasing factor analog in water
11/21/2000US6150325 Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compositions
11/21/2000US6150132 Vector coding polypeptides for the diagnosis and treatment of allergies and atherosclerosis; for the prevention of graft ejection and injuries to stem cell caused by anticarcinogenic agents
11/21/2000US6150101 Methods of identifying a composition that alters connective tissue growth factor expression
11/21/2000US6149947 Compositions of oak bark extract related synthetic compositions and method of using same
11/21/2000US6149902 Manipulation of non-terminally differentiated cells using the notch pathway
11/21/2000CA2213411C Reduction of hair growth
11/21/2000CA2187309C Tropane-2-aldoxime derivatives as neurotransmitter reuptake inhibitors
11/21/2000CA2038578C Delivery of agents
11/21/2000CA2024631C Double-coated granules of disodium pamidronate
11/16/2000WO2000068691A1 Methods for screening gaba-modulatory compounds for specified pharmacological activities
11/16/2000WO2000068399A2 Vector-mediated delivery of integrating transposon sequences
11/16/2000WO2000068387A2 Nucleic acids and proteins with interferon-beta activity
11/16/2000WO2000068385A2 Novel nucleic acids and proteins with growth hormone activity
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068261A2 Attenuated microorganisms for the treatment of infection
11/16/2000WO2000068255A2 Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application
11/16/2000WO2000068245A1 14β-H-STEROLS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USE OF THESE DERIVATIVES FOR THE PREPARATION OF MEIOSIS REGULATING MEDICAMENTS
11/16/2000WO2000068241A1 Processes for the synthesis of oligomers using phusphoramidite compositions
11/16/2000WO2000068231A1 Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
11/16/2000WO2000068226A1 1-(p-thienylbenzyl)-imidazoles as angiotensin-(1-7) receptor agonists, method for the production and the utilization thereof and pharmaceutical preparations containing said compounds
11/16/2000WO2000068223A1 Ureas and their use as cell adhesion modulators
11/16/2000WO2000068215A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000WO2000068209A2 1,5-benzodiazepine derivatives as cck-a receptor agonists
11/16/2000WO2000068208A1 Pyrimidinones derivatives for the treatment of atherosclerosis
11/16/2000WO2000068206A1 Heterocyclically substituted benzimidazoles, the production and application thereof
11/16/2000WO2000068202A1 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
11/16/2000WO2000068201A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000WO2000068200A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000WO2000068199A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000WO2000068198A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000WO2000068195A2 Substituted pyrrolidines as cell adhesion inhibitors
11/16/2000WO2000068194A1 Iminocyclitol inhibitors of hexoaminidase and glycosidase
11/16/2000WO2000068185A1 A structure-based approach to design inhibitors of protein-processivity factor interactions
11/16/2000WO2000067798A2 Enhanced delivery of nucleic acid-based drugs
11/16/2000WO2000067791A1 Ccr4 antagonists in sepsis
11/16/2000WO2000067790A1 Method for treating tnf-receptor type-2-induced diseases
11/16/2000WO2000067776A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000WO2000067769A1 Enhanced survival of cancer patients treated with erythropoietin and antitumor agents
11/16/2000WO2000067762A2 Selenium-containing pro-drugs for cancer therapy
11/16/2000WO2000067755A1 Cyclic amidines useful as nmda nr2b antagonists
11/16/2000WO2000067746A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000067743A1 Radical scavenger
11/16/2000WO2000067739A2 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects
11/16/2000WO2000067738A2 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
11/16/2000WO2000067736A2 Therapeutic use of an inhibitor or an antagonist of an abc protein in bone
11/16/2000WO2000067735A2 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION
11/16/2000WO2000067734A2 Use of phthalazine derivatives
11/16/2000WO2000067728A2 Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
11/16/2000WO2000067698A2 Method for controlling the fidelity and execution of reverse transcriptase by incorporating and polymerising nucleotide analogues acceptable as substrates without blocking its elongation
11/16/2000WO2000048996A3 β-ALANINE DERIVATIVES
11/16/2000WO2000046376A3 Particles for gene therapy
11/16/2000WO2000043501A3 Ribozymes directed against the catalytic subunit of the human telomerase (htert)
11/16/2000WO2000042179A3 Complex-forming proteins
11/16/2000WO2000042168A3 Bifidobacterium in the treatment of inflammatory disease
11/16/2000WO2000041669A3 Benzimidazole vascular damaging agents
11/16/2000WO2000041469A3 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS
11/16/2000WO2000038665A3 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
11/16/2000WO2000038536A3 Inhibitors of the bitter taste response
11/16/2000WO2000037613A3 Human akt-3
11/16/2000WO2000037059A3 Compositions and methods to inactivate n-type calcium channels
11/16/2000WO2000037025A3 Antibodies to truncated vegf-d and uses thereof
1 ... 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 ... 1564